OGI - Organigram Global Inc.
RxSight (NASDAQ: RXST - Get Free Report) and Organigram Global (NASDAQ: OGI - Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, valuation, institutional ownership, earnings, dividends, analyst recommendations and profitability. Earnings and Valuation This table compares RxSight and
Organigram Global Inc. (OGI:CA) Discusses Strategic Priorities, Growth Initiatives, and Insights from Production Facilities Transcript
Organigram Global NASDAQ: OGI outlined a strategy centered on protecting its Canadian market position while increasing profitability, expanding internationally through its Sanity Group acquisition, improving manufacturing efficiency and applying stricter capital-allocation discipline.
TORONTO--(BUSINESS WIRE)--Organigram Global Inc. (NASDAQ: OGI) (TSX: OGI) (the "Company" or "Organigram") is pleased to announce that the 2026 OG Investor Session will premiere today, September 30, 2026, at 4:00 p.m. ET on the Company's X account at https://x.com/Organigram_Inc. The session will also be simulcast on Organigram's LinkedIn and YouTube channels. “We designed this year's OG Investor Session around the questions we hear most often from investors — where the next phase of growth come.
KORU Medical Systems (NASDAQ: KRMD - Get Free Report) and Organigram Global (NASDAQ: OGI - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, institutional ownership, profitability, earnings, analyst recommendations, valuation and risk. Profitability This table compares KORU Medical
TORONTO--(BUSINESS WIRE)--Organigram Global Inc. (NASDAQ: OGI) (TSX: OGI) (the "Company" or "Organigram"), Canada's #1 cannabis company by market share and a growing global cannabis platform, today announced details of its 2026 OG Investor Session. “Since our last investor session, we've welcomed a new leadership team, completed our first full quarter with Sanity Group, and sharpened our strategy for the years ahead. We look forward to updating our stakeholders on how we're aligning Organigram.
Organigram Global Inc. (NASDAQ: OGI) (TSX: OGI) (âOrganigramâ or the âCompanyâ) today announced an important milestone in its global growth strategy thr
TORONTO--(BUSINESS WIRE)--Organigram Global Inc. (NASDAQ: OGI) (TSX: OGI) (“Organigram” or the “Company”) today announced an important milestone in its global growth strategy through the accelerated integration of Sanity Group GmbH (“Sanity”) and the alignment of leadership, operations and market development activities across the combined organization. To support the combined organization, Organigram has appointed Finn Age Hänsel as President, Rest of World & Chief Strategy Officer, and Adr.
OrganiGram (OGI) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.01. This compares to a loss of $0.03 per share a year ago.
Organigram Global NASDAQ: OGI reported record third-quarter fiscal 2026 revenue and adjusted EBITDA, aided by the consolidation of Germany-based Sanity Group and improving performance in several Canadian cannabis categories.
TORONTO--(BUSINESS WIRE)--Organigram Global Inc. (NASDAQ: OGI) (TSX: OGI), (the “Company” or “Organigram”), Canada's #1 cannabis company by market share2 and a growing global cannabis platform following its acquisition of Sanity Group GmbH (“Sanity” or “Sanity Group”), today announced its results for the third quarter ended June 30, 2026 (“Q3 Fiscal 2026” or “Q3”). Q3 FISCAL 2026 HIGHLIGHTS Gross Revenue: $145.1 million (+32% year-over-year). Net Revenue: $105.8 million (+49% year-over-year). A.
TORONTO--(BUSINESS WIRE)--Organigram Global Inc. (NASDAQ: OGI) (TSX: OGI), (the “Company” or “Organigram”), Canada's #1 cannabis company by market share and a growing global cannabis platform following its acquisition of Sanity Group GmbH (“Sanity”), announced today it will report earnings results for its third quarter ended June 30, 2026, on Tuesday, August 11, 2026, prior to market open. The Company will host a conference call to discuss its results with details as follows: Date: Tuesday, Aug.
TORONTO--(BUSINESS WIRE)--Organigram Global Inc. (NASDAQ: OGI) (TSX: OGI), (the “Company” or “Organigram”), Canada's #1 cannabis company by market share and a growing global cannabis platform following its acquisition of Sanity Group GmbH (“Sanity”), today provided a business update highlighting initial operating performance from Sanity, continued strength in its Canadian business, and upcoming investor engagement. "The first quarter following the acquisition of Sanity marks an important milest.
Organigram's disappointing Q2 earnings could be a direct result of its record harvests overwhelming downstream capacity. Expected Sanity contribution to full-year revenue and adjusted EBITDA guidance suggests that organic growth may turn negative in the second half of FY 2026. Persistent out-of-spec exports point to a severe bottleneck in drying capacity, where overcrowded drying rooms are fostering microbial growth and driving inconsistent drying.
Organigram Global Inc. (OGI:CA) Q2 2026 Earnings Call Transcript
Organigram Global Inc. (NASDAQ:OGI) reported weaker second-quarter fiscal 2026 results as declining vape and infused pre-roll sales weighed on revenue and profitability.
OrganiGram (OGI) came out with a quarterly loss of $0.01 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.05 per share a year ago.
Organigram Global NASDAQ: OGI reported a weaker second quarter for fiscal 2026, with management attributing the decline to operational issues in key product categories, softer Canadian cannabis market growth and continued challenges with international flower specifications.
TORONTO--(BUSINESS WIRE)--Organigram Global Inc. (NASDAQ: OGI) (TSX: OGI), (the “Company” or “Organigram”), Canada's #1 cannabis company by market share1, is pleased to announce its results for the second quarter ended March 31, 2026 (“Q2 Fiscal 2026” or "Q2"). Q2 FISCAL 2026 HIGHLIGHTS Gross Revenue: $93.3 million (-9% year-over-year). Net Revenue: $59.8 million (-9% year-over-year). International Revenue: $6.1 million (0% year-over-year). Adjusted EBITDA2: $0.9 million (-82% year-over-year).
TORONTO--(BUSINESS WIRE)--Organigram Global Inc. (NASDAQ: OGI) (TSX: OGI), (the “Company” or “Organigram”), Canada's #1 cannabis company by market share, announced today it will report earnings results for its second quarter fiscal 2026 ended March 31, 2026, on Tuesday, May 12, 2026, prior to market open. The Company will host a conference call to discuss its results with details as follows: Date: Tuesday, May 12, 2026 Time: 8:00 am Eastern Time To register for the conference call, please use t.